WEKO3
アイテム
{"_buckets": {"deposit": "91f5fca0-40f7-4026-8bfc-894297927017"}, "_deposit": {"created_by": 1, "id": "49516", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "49516"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00049516", "sets": ["1"]}, "author_link": ["797101", "797098", "797091", "797093", "797100", "797109", "797113", "797095", "797099", "797110", "797088", "797097", "797103", "797105", "797107", "797096", "797112", "797094", "797108", "797102", "797114", "797104", "797092", "797089", "797090", "797111", "797087", "797106"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2019-01", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "1", "bibliographicPageEnd": "81", "bibliographicPageStart": "76", "bibliographicVolumeNumber": "10", "bibliographic_titles": [{"bibliographic_title": "Oncotarget"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "The aims of this study were to clarify the safety and efficacy of 12-fraction carbon-ion radiotherapy (CIRT) for primary renal cell carcinoma (RCC) and to confirm the recommended dose in a prospective clinical trial.\nThis clinical trial was planned as a non-randomized, open-label, single-center phase I/II study of CIRT monotherapy. The incidence of acute adverse events was the primary endpoint. Dose-limiting toxicities (DLTs) were defined as grade ≥3 skin, gastrointestinal tract, or urologic adverse events.\nBased on the eligibility criteria, 8 patients with primary RCC, including 3 medically inoperable patients and 5 patients with tumors \u003e4 cm, were enrolled. Of the 8 patients, 5 were treated with 66 Gy (relative biological effectiveness [RBE]), and subsequently, the dose was escalated to 72 Gy (RBE) for the remaining 3 patients. The median follow-up time was 43.1 months. No DLTs were observed at any dose level though the end of follow-up. Although 1 patient died of pneumonia 3 months after CIRT, which was determined to be unrelated to CIRT, no grade 3 or higher adverse events were observed, and both local control and cancer-specific survival rates were 100%.\nIn conclusion, the safety and efficacy of CIRT hypofractionation using 12-fractions for the treatment of eligible RCC patients, including those with inoperable or tumor size \u003e4 cm, were confirmed in this prospective trial, and a recommended dose of 72 Gy (RBE) was established.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Inpact Journals"}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.18632/oncotarget.26539", "subitem_relation_type_select": "DOI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1949-2553", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kasuya, Goro"}], "nameIdentifiers": [{"nameIdentifier": "797087", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "797088", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nomiya, Takuma"}], "nameIdentifiers": [{"nameIdentifier": "797089", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Makishima, Hirokazu"}], "nameIdentifiers": [{"nameIdentifier": "797090", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Haruyama, Yasuo"}], "nameIdentifiers": [{"nameIdentifier": "797091", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kobashi, Gen"}], "nameIdentifiers": [{"nameIdentifier": "797092", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hayashi, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "797093", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ebner, Daniel"}], "nameIdentifiers": [{"nameIdentifier": "797094", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Omatsu, Tokuhiko"}], "nameIdentifiers": [{"nameIdentifier": "797095", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kishimoto, Riwa"}], "nameIdentifiers": [{"nameIdentifier": "797096", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yasuda, Shigeo"}], "nameIdentifiers": [{"nameIdentifier": "797097", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Igarashi, Tatsuo"}], "nameIdentifiers": [{"nameIdentifier": "797098", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oya, Mototsugu"}], "nameIdentifiers": [{"nameIdentifier": "797099", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Akakura, Koichiro"}], "nameIdentifiers": [{"nameIdentifier": "797100", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Suzuki, Hiroyoshi"}], "nameIdentifiers": [{"nameIdentifier": "797101", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ichikawa, Tomohiko"}], "nameIdentifiers": [{"nameIdentifier": "797102", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimazaki, Jun"}], "nameIdentifiers": [{"nameIdentifier": "797103", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "797104", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Group for Genitourinary Tumors, Working"}], "nameIdentifiers": [{"nameIdentifier": "797105", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kasuya, Goro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "797106", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Hiroshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "797107", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nomiya, Takuma", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "797108", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Makishima, Hirokazu", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "797109", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ebner, Daniel", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "797110", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Omatsu, Tokuhiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "797111", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kishimoto, Riwa", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "797112", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yasuda, Shigeo", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "797113", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "797114", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/49516", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-12-28"}, "publish_date": "2018-12-28", "publish_status": "0", "recid": "49516", "relation": {}, "relation_version_is_last": true, "title": ["Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma"], "weko_shared_id": -1}
Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma
https://repo.qst.go.jp/records/49516
https://repo.qst.go.jp/records/49516cb17a8ea-96c9-4d40-ac9b-73ba7dd8a4e8
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2018-12-28 | |||||
タイトル | ||||||
タイトル | Prospective clinical trial of 12-fraction carbon-ion radiotherapy for primary renal cell carcinoma | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Kasuya, Goro
× Kasuya, Goro× Tsuji, Hiroshi× Nomiya, Takuma× Makishima, Hirokazu× Haruyama, Yasuo× Kobashi, Gen× Hayashi, Kazuhiko× Ebner, Daniel× Omatsu, Tokuhiko× Kishimoto, Riwa× Yasuda, Shigeo× Igarashi, Tatsuo× Oya, Mototsugu× Akakura, Koichiro× Suzuki, Hiroyoshi× Ichikawa, Tomohiko× Shimazaki, Jun× Kamada, Tadashi× Group for Genitourinary Tumors, Working× Kasuya, Goro× Tsuji, Hiroshi× Nomiya, Takuma× Makishima, Hirokazu× Ebner, Daniel× Omatsu, Tokuhiko× Kishimoto, Riwa× Yasuda, Shigeo× Kamada, Tadashi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | The aims of this study were to clarify the safety and efficacy of 12-fraction carbon-ion radiotherapy (CIRT) for primary renal cell carcinoma (RCC) and to confirm the recommended dose in a prospective clinical trial. This clinical trial was planned as a non-randomized, open-label, single-center phase I/II study of CIRT monotherapy. The incidence of acute adverse events was the primary endpoint. Dose-limiting toxicities (DLTs) were defined as grade ≥3 skin, gastrointestinal tract, or urologic adverse events. Based on the eligibility criteria, 8 patients with primary RCC, including 3 medically inoperable patients and 5 patients with tumors >4 cm, were enrolled. Of the 8 patients, 5 were treated with 66 Gy (relative biological effectiveness [RBE]), and subsequently, the dose was escalated to 72 Gy (RBE) for the remaining 3 patients. The median follow-up time was 43.1 months. No DLTs were observed at any dose level though the end of follow-up. Although 1 patient died of pneumonia 3 months after CIRT, which was determined to be unrelated to CIRT, no grade 3 or higher adverse events were observed, and both local control and cancer-specific survival rates were 100%. In conclusion, the safety and efficacy of CIRT hypofractionation using 12-fractions for the treatment of eligible RCC patients, including those with inoperable or tumor size >4 cm, were confirmed in this prospective trial, and a recommended dose of 72 Gy (RBE) was established. |
|||||
書誌情報 |
Oncotarget 巻 10, 号 1, p. 76-81, 発行日 2019-01 |
|||||
出版者 | ||||||
出版者 | Inpact Journals | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1949-2553 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.18632/oncotarget.26539 |